Category: Business News

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

Perrigo also said it will review its API business, which provides differentiated active pharmaceutical ingredients and finished dosage forms for the branded and generic industries. Perrigo , the Dublin-based manufacturer of over-the-counter drugs, announced Monday it will divest its royalty stream for multiple sclerosis drug Tysabri to an affiliate of Royalty Pharma for up to $2.85 billion.

Trump urges insurers to work together to a save Americans from Obamacarea

Health and Human Services Secretary Tom Price and Aetna CEO Mark Bertolini listen to U.S. President Donald Trump speak during a meeting with health insurance company CEOs. President Trump met with major health insurers Monday morning, in the midst of intensifying public pressure to preserve the law political divisions over how to best dismantle and replace President Obama’s signature domestic policy achievement, the Affordable Care Act.

11 insider facts most flight attendants know – and you…

But by talking to these veteran globetrotters, as well as scouring Reddit and various articles, we were able to unearth 12 lesser-known facts about flying. Whether you want more attentive service or to avoid getting kicked off your flight, read on for the inside scoop: Annette Long, a flight attendant with 13 years of experience, tells Business Insider that, though opening a door mid-flight is impossible to do, trying it will still get you into trouble.

Cigna Sues Anthem After Ending Deal; Anthem Says It Has No Right

Simmering tensions between Anthem Inc. and Cigna Corp. exploded Tuesday as Cigna sued to end their $48 billion deal, and Anthem moments later said the smaller health insurer had no right to do so and that it would fight to keep the merger alive. As part of its lawsuit, Cigna is seeking a $1.85 billion breakup fee, plus $13 billion in additional damages it says are owed after “the path for regulatory approval of the transaction was fatally compromised” by Anthem.

Why Panera Bread, Tesaro, and Universal Corp. Jumped Today

The stock market was narrowly mixed on Wednesday, with the Dow Jones Industrials losing ground but the S&P 500 and Nasdaq Composite posting modest gains on the day. Earnings season has had positive effects on some stocks and negative ones on others, but the general uncertainty in the political realm and its potential impact on future economic growth continues to hold the market back from pushing further toward record-high territory.

Sanofi Profit May Drop This Year as Lantus Blockbuster Ages

Sanofi said profit may drop this year as the French drugmaker pursues new drivers of growth to offset declines for its best-selling diabetes treatment Lantus. Sanofi expects earnings per share excluding some items to be stable to down as much as 3 percent at constant exchange rates, the Paris-based company said in a statement on Wednesday.

Haven’t Gotten Your W-2? Take These Steps

You’re ready to file your taxes – except for one thing: You’re still awaiting an IRS Form W-2 from an employer. Each January, companies issue W-2s to inform workers, and Uncle Sam, of the amount of money the worker made during the previous year and how much in income, Social Security and Medicare taxes was withheld.

Roche Sees Sales Boost in 2017 With New Lung Drug on U.S. Market

Roche Holding AG pointed toward rising sales this year as its new cancer immune therapy Tecentriq gains wider use for lung tumors. Revenue will probably rise by a low to mid-single digit percentage at constant exchange rates, the same pace as earnings per share excluding some items, the Basel, Switzerland-based company said in a statement Wednesday.

Pfizer Seeks Deals as Generic Versions Hurts Older Drugs’ Sales

Pfizer Inc. expects more generic competition for its established drugs in 2017, and the company’s deal-making to gain products may continue to thrive. After posting fourth-quarter earnings and a forecast that were short of analysts’ estimates, New York-based Pfizer said it would continue to pursue deals, regardless of their size, as long as they create shareholder value.

Here’s What Expect From Anthem, Cigna, Aetna, Humana Earnings

Analysts say to watch for 2017 guidance for signals on how insurers believe President Trump will handle the repeal of the Affordable Care Act. As earnings season heats up, analysts say to watch the Big Five health insurers for guidance on how they will respond to impending changes to the Affordable Care Act ushered in by the Trump administration.

What Will You Hear on Pfizer’s Fourth-Quarter Call Tuesday?

What’s likely to be at the top of investors’ minds during Pfizer’s fourth-quarter conference call Tuesday morning? How about Pfizer’s plans to overcome oncoming competition involving several important products while navigating what remains a difficult pricing environment? Clues from CEO Ian Read and the management team about the company’s capital deployment plans ought to be of high interest, too. In the wake of continued speculation around the sale of its consumer business, which operates as part of its Innovative Health segment and is home to the Chapstick and Advil brands, potential strategic M&A and divestitures could make up for slowing revenue growth seen across existing therapies.

Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company

What will it do with all of that cash generated from its hepatitis C portfolio? It surely has to do something, right? The pressure has only increased after the company cut prices for the drugs in an effort to keep the competition at bay, which resulted in a 30% decline in hepatitis C revenue in the third quarter of 2016 compared with the year-ago period. Throw in a steady stream of pipeline failures, and it’s easy to explain Wall Street’s lust for M&A.

3 Biotechs Likely to Be Acquired in 2017

The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid . Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology The number of big companies battling to acquire Medivationin 2016 shows that the oncology space is hot.

Trump Adviser Kellyanne Conway Says Obamacare – Penalty’ Will End

Kellyanne Conway, a key adviser to President Donald Trump, said the new administration plans to end the Affordable Care Act’s requirement that most people have health insurance, a step that could destabilize the law’s markets. Conway, in an interview airing Sunday on NBC News’ “Sunday Today With Willie Geist,” appeared to indicate that the law’s requirement that most employers offer coverage to their full-time workers would also end.

article

As President Donald Trump steps into the Oval Office, a number of issues loom large, but one may stand out head and shoulders above the pack: the United States’ growing national debt. According to the USDebtClock.org, the national debt is rapidly closing in on $20 trillion, which works out to more than $61,300 for every man, woman, and child in the U.S. and nearly $167,000 for every taxpayer in the country.

BAT agrees to buy Reynolds for $49 billion

British American Tobacco has agreed a $49.4 billion takeover of U.S. rival Reynolds American Inc , creating the world’s biggest listed tobacco company after it increased an earlier offer by more than $2 billion. BAT, which already owned 42 percent of Reynolds, will pay $29.44 in cash and 0.5260 BAT shares for each Reynolds share, it said, a 26 percent premium over the price of the stock on Oct. 20, the day before BAT’s first offer was made public.

U.S. House Votes to Begin Repealing Obamacare

U.S. House Republicans on Friday won passage of a measure starting the process of dismantling Obamacare, despite concerns about not having a ready replacement and the potential financial cost of repealing repealing Democratic President Barack Obama’s landmark health insurance law. The House of Representatives voted 227-198 to instruct committees to draft legislation by a target date of Jan. 27 that would repeal the 2010 Affordable Health Care Act, popularly known as Obamacare.

3 Little-Known Pharmaceutical Companies to Put on Your Radar

Over the past year, the best-performing drugmaker stocks all have had one thing in common: They received very little attention before providing patient investors windfall gains. Being considered insignificant in itself isn’t a great reason to scoop up shares of Teligent Brian Feroldi : Being called a “specialty generic” drug manufacturer might sound oxymoronic, but Teligent has stumbled on a clever business strategy that could make it a great stock to put on your watch list.

For Merck, Keytruda Is ‘Extraordinarily Positive’ : More Squawk From Jim Cramer

Merck’s lung cancer treatment will get a speedy review by the FDA, but it ‘knows better than to go out and give false hope,’ TheStreet’s Jim Cramer said. Shares of Merck were higher in late morning trading Wednesday, after the company announced the U.S. Food and Drug Administration would make a decision by May 10 on its lung cancer treatment that combines the immune system-boosting drug Keytruda with chemotherapy.

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer

Sales of Regeneron’s lead product have been tapering off, but a handful of potential blockbusters could provide some big gains in 2017 and beyond. The pharma giant, meanwhile, also has some exciting growth drivers in its lineup, but an aging product line will make big gains difficult going forward.